Services

Screening

An EU-OPENSCREEN screening site will take the robust, miniaturised assay together with established orthogonal and counter screens through the high throughput screening (HTS) process, followed by confirmatory (dose response) and counter screening (identical assay without the target or with non-functional target), until a final list of confirmed hit compounds is established.
 

This process includes the following services:

  • HTS (of the entire EU-OPENSCREEN chemical collection)
  • In silico profiling, including basic chemoinformatic analysis and identification of frequent hitters and other potential false positives
  • Hit selection
  • Confirmatory screening, including orthogonal assay and IC/EC50 determination
  • Basic counter screening
  • Basic SAR based on screening data
  • QC of confirmed hits for a biochemical screen, the hit confirmation process includes testing for activity in a cell-based model.
  • Fragment based library screening
  • Virtual screening

For more information you can watch our introductory video on high-throughput-screening (HTS) here.

 

Screening partner sites

CZECH REPUBLIC


Palacký University Olomouc, Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine (IMTM)

Dr. Marian Hajduch, Dr. Petr Dzubak

Information PDF

 

Institute of Molecular Genetics AS CR, v. v. i. (IMG)

Dr. Petr Bartůněk

Information PDF 

Germany


Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP)/MDC Berlin, Chemical Biology – Screening Unit

Dr. Jens Peter von Kries

Information PDF

 

Helmholtz-Zentrum für Infektionsforschung GmbH (HZI), Department of Chemical Biology (CBIO)

Prof. Mark Brönstrup

Information PDF

 

Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP) – Drug Discovery - Screening Port

Dr. Philip Gribbon

Information PDF

DENMARK


Biotech Research and Innovation Centre (BRIC), Prof. Krister Wennerberg

Dr. Cornelia Steinhauer

Site information PDF

SPAIN


FUNDACION MEDINA, Screening and target validation, Microbiology and Chemistry

Dr. Olga Genilloud

Information PDF

 

Prince Felipe Research Center (CIPF), Advanced Therapies Program, Screening Platform

Dr. María J. Vicent,

Information PDF

 

University of Santiago de Compostela, BioFarma Research Group

Prof. Mabel Loza

Information PDF

FINLAND


University of Helsinki, Faculty of Pharmacy, Division of Pharmaceutical Biosciences

Prof. Arto Urtti

Information PDF

 

Institute for Molecular Medicine Finland (FIMM), High Throughput Biomedicine (HTB) unit

Prof. Päivi Tammela

Information PDF 

Norway


University of Bergen, Department of Biomedicine, Faculty of Medicine and Dentistry

Prof. Aurora Martinez

Information PDF

 

University of Oslo, Faculty of Medicine, Biotechnology Centre of Oslo (BiO) and Centre for Molecular Medicine (NCMM)

Dr. Johannes Landskron

Information PDF

  

Arctic University of Norway, Faculty of Biosciences, Economics and Fisheries

Prof. Jeanette H. Andersen

Information PDF

 

SINTEF Materials and Chemistry

Dr. ing. Geir Klinkenberg

Information PDF

POLAND


Institute of Medical Biology, Polish Academy of Sciences (IMB PAS), Screening laboratory for anti-viral and anti-bacterial compounds

Prof. Dr. Zbigniew J. Leśnikowski

Information PDF

 

Institute of Bioorganic Chemistry (IBCH), Polish Academy of Science

Dr. Radosław Pilarski, Dr. Jacek Kolanowski

Information PDF